Is hepatic transplantation justified for primary liver cancer?
A concise, yet objective overview of Hepatocellular Carcinoma (HCC) treatment in 2006 with an intent to transplant is presented. The most significant variables impacting on the use of hepatic transplantation as therapy for primary liver cancer are developed under the headings of: Staging Criteria; Organ allocation; Transplant dropout minimization therapies; and Effects on the HCC general population. The pertinent medical literature and update of an ongoing intent-to-treat HCC with transplant single center randomized control trial are reviewed.
Fisher
Robert A
RA
Department of Surgery, Division of Transplant Surgery, Virginia Commonwealth University Medical Center, Richmond, Virginia, USA. rafisher@vcu.edu
Maluf
Daniel G
DG
Wolfe
Luke
L
Williams
Bridgette
B
Cotterell
Adrian
A
Stravitz
R Todd
RT
Heuman
Douglas
D
Posner
Marc
M
D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation; D019520:Living Donors; D009367:Neoplasm Staging; D010352:Patient Dropouts; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D009927:Tissue and Organ Procurement; D014850:Waiting Lists